Together, these data demonstrated that TGF-β signaling is correlated with a reduced patient prognosis, is elevated in TNBC compared to other breast cancer subtypes and is correlated with reduced patient prognosis in TNBC patients, supporting the need for the advancement of therapeutic modulation of TGF-β [41,42,48]. Here, TGFB1 is linked to breast carcinoma.